[1] 贾继东. 肝纤维化和肝硬化.//姚光弼.临床肝脏病学.上海:上海科学技术出版社,2004:460.
[2] 谭友文, 吴建成. 刀豆蛋白A诱导小鼠肝纤维化动物模型的建立.中国肝脏病杂志(电子版), 2008, 1: 12-17.
[3] Tiegs G, Hentschel J, Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest,1992, 90: 196-203.
[4] Wolf D, Hallmann R, Sass G, et al. TNF-alpha-induced expression of adhesion molecules in the liver is under the control of TNFR1--relevance for concanavalin A-induced hepatitis. J Immunol, 2001, 166: 1300-1307.
[5] 胡国芬,王建平.川芎嗪的药理作用及临床应用进展.中国药物与临床,2006,6: 773-774.
[6] 马进, 郑仕中, 陆茵,等. 川芎嗪抑制肝纤维化作用机制的研究进展. 中国临床药理学杂志, 2010, 26: 395-398.
[7] Jatiani SS, Baker SJ, Silverman LR, et al. Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes Cancer, 2010, 1: 979- 993.
[8] Zhang W, Tsuda M, Yang GX, et al. Deletion of interleukin-6 in mice with the dominant negative form of transforming growth factor beta receptor II improves colitis but exacerbates autoimmune cholangitis. Hepatology, 2010, 52: 215-222.
[9] Weng H, Mertens PR, Gressner AM, et al. IFN-gamma abrogates profibrogenic TGF-beta signaling in liver by targeting expression of inhibitory and receptor Smads. J Hepatol, 2007, 46:295-303.
[10] 李建高, 樊必夫, 管丽华,等. 慢性乙型肝炎、肝硬化、肝癌患者血清IL-8、IL-10和leptin水平变化及其临床意义. 放射免疫学杂志, 2012, 25: 127-130. |
